Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.C. Penney (JCP) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Kimberly Greenberger saying valuation appears more balanced following a 14% decline year-to-date and potential catalysts ahead. 2. Regeneron (REGN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying that while Eylea growth is slowing, new approvals are coming. The analyst expects Dupixent approval in atopic dermatitis by the March 29 FDA action date and Phase III Liberty Asthma Quest data and potential supplemental Biologics License Application by year-end. 3. Petrobras (PBR) upgraded to Overweight from Neutral at JPMorgan with analyst Rodolfo Angele saying the shares are back to September 2016 levels despite "many positive" developments since then. 4. Nucor (NUE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Kurtz saying Nucor has more favorable risk/reward than AK Steel (AKS), which was downgraded to Equal Weight, given its low cost profile, margin stability, attractive end market mix, and potential benefits from favorable rulings on ongoing rebar and plate trade cases. 5. Allscripts (MDRX) upgraded to Buy from Neutral at Dougherty with analyst Gene Mannheimer citing a strong 2017 outlook partly due to Sunrise expansion, checks that indicate traction in the Allscripts open platform, and opportunities for growth from the NetSmart joint venture. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.